Home > Cardiology > ACC 2019 > Acute and Stable Ischaemic Heart Disease > Patients with polyvascular disease significantly undertreated with lipid lowering therapies

Patients with polyvascular disease significantly undertreated with lipid lowering therapies

Conference
ACC 2019

Lowering of low-density lipoprotein (LDL) has been shown to reduce cardiovascular (CV) events and all-cause mortality in patients who suffer from atherosclerotic disease [1]. Patients with polyvascular disease in particular have a significantly higher rate of major adverse cardiovascular events than patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease alone. Despite strong guideline recommendations and clinical trial data, many patients are unable to receive adequate LDL lowering therapy, which results in excess CV risk.

Peterson et al. aimed to determine the LDL treatment patterns over time in patients with polyvascular disease in the USA. In the multicentre, observational *Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management* (GOULD) Registry of atherosclerotic cardiovascular disease patients on lipid therapy, baseline treatment was assessed by medical ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on